Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation versus observation after PET-negative complete remission in older newly diagnosed DLBCL
NL-OMON40206Phase 3Active, not recruiting
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of ibritumomab tiuxetan, sponsored by Spectrum Pharmaceuticals, Inc. Started May 2014; status: active, not recruiting.
02
Drugs
ibritumomab tiuxetan
Beyond the preview
Go deeper on NL-OMON40206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40206.